Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Net Income (2016 - 2025)

vTv Therapeutics' Net Income history spans 12 years, with the latest figure at -$7.1 million for Q4 2025.

  • For Q4 2025, Net Income fell 60.87% year-over-year to -$7.1 million; the TTM value through Dec 2025 reached -$31.1 million, down 36.89%, while the annual FY2025 figure was -$31.1 million, 36.89% down from the prior year.
  • Net Income for Q4 2025 was -$7.1 million at vTv Therapeutics, up from -$10.3 million in the prior quarter.
  • Across five years, Net Income topped out at -$841000.0 in Q2 2021 and bottomed at -$10.3 million in Q3 2025.
  • The 5-year median for Net Income is -$6.1 million (2022), against an average of -$6.1 million.
  • The largest YoY upside for Net Income was 83.15% in 2021 against a maximum downside of 689.17% in 2021.
  • A 5-year view of Net Income shows it stood at -$9.5 million in 2021, then surged by 35.68% to -$6.1 million in 2022, then rose by 27.08% to -$4.4 million in 2023, then grew by 0.09% to -$4.4 million in 2024, then tumbled by 60.87% to -$7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Net Income are -$7.1 million (Q4 2025), -$10.3 million (Q3 2025), and -$7.4 million (Q2 2025).